TTOO Receivables Turnover vs Net Income Analysis
TTOO Stock | USD 2.72 0.44 13.92% |
T2 Biosystms financial indicator trend analysis is much more than just breaking down T2 Biosystms prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether T2 Biosystms is a good investment. Please check the relationship between T2 Biosystms Receivables Turnover and its Net Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
Receivables Turnover vs Net Income
Receivables Turnover vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of T2 Biosystms Receivables Turnover account and Net Income. At this time, the significance of the direction appears to have pay attention.
The correlation between T2 Biosystms' Receivables Turnover and Net Income is -0.77. Overlapping area represents the amount of variation of Receivables Turnover that can explain the historical movement of Net Income in the same time period over historical financial statements of T2 Biosystms, assuming nothing else is changed. The correlation between historical values of T2 Biosystms' Receivables Turnover and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Receivables Turnover of T2 Biosystms are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Receivables Turnover i.e., T2 Biosystms' Receivables Turnover and Net Income go up and down completely randomly.
Correlation Coefficient | -0.77 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Receivables Turnover
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in T2 Biosystms financial statement analysis. It represents the amount of money remaining after all of T2 Biosystms operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from T2 Biosystms' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into T2 Biosystms current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.As of the 23rd of April 2024, Enterprise Value is likely to grow to about 75.5 M, while Selling General Administrative is likely to drop about 26 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 6.6M | 6.1M | 5.3M | 4.9M | Depreciation And Amortization | 318K | 39K | 859K | 843.9K |
T2 Biosystms fundamental ratios Correlations
Click cells to compare fundamentals
T2 Biosystms Account Relationship Matchups
High Positive Relationship
High Negative Relationship
T2 Biosystms fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 28.5M | 79.1M | 60.5M | 34.4M | 34.8M | 43.7M | |
Short Long Term Debt Total | 44.8M | 55.8M | 57.1M | 59.2M | 49.5M | 42.0M | |
Other Current Liab | 13.6M | 6.4M | 7.2M | 7.7M | 11.5M | 7.1M | |
Total Current Liabilities | 60.6M | 9.8M | 11.7M | 10.5M | 56.2M | 59.0M | |
Total Stockholder Equity | (34.0M) | 8.7M | (12.9M) | (40.0M) | (28.0M) | (26.6M) | |
Other Liab | 46K | 4.8M | 4.6M | 4.9M | 5.6M | 5.9M | |
Property Plant And Equipment Net | 9.2M | 14.8M | 14.4M | 13.3M | 9.1M | 9.8M | |
Net Debt | 33.7M | 39.0M | 34.9M | 48.9M | 33.8M | 35.5M | |
Retained Earnings | (376.2M) | (423.0M) | (472.2M) | (534.5M) | (584.3M) | (555.1M) | |
Accounts Payable | 3.8M | 2.1M | 2.8M | 1.3M | 1.5M | 1.6M | |
Cash | 11.0M | 16.8M | 22.2M | 10.3M | 15.7M | 28.6M | |
Non Current Assets Total | 9.6M | 25.5M | 16.1M | 15.0M | 9.7M | 11.6M | |
Cash And Short Term Investments | 11.0M | 42.2M | 32.2M | 10.3M | 15.7M | 31.0M | |
Common Stock Total Equity | 36K | 44K | 51K | 147K | 169.1K | 177.5K | |
Common Stock Shares Outstanding | 9.1K | 24.3K | 31.8K | 51.0K | 2.6M | 2.7M | |
Liabilities And Stockholders Equity | 28.5M | 79.1M | 60.5M | 34.4M | 34.8M | 43.7M | |
Non Current Liabilities Total | 1.9M | 60.6M | 61.8M | 63.9M | 6.7M | 6.3M | |
Other Current Assets | 1.4M | 2.7M | 3.1M | 2.6M | 3.2M | 1.7M | |
Other Stockholder Equity | 342.1M | 431.5M | 459.2M | 494.6M | 556.3M | 315.0M | |
Total Liab | 62.5M | 70.4M | 73.4M | 74.4M | 62.8M | 50.8M | |
Property Plant And Equipment Gross | 9.2M | 14.8M | 14.4M | 13.3M | 23.9M | 25.1M | |
Total Current Assets | 18.9M | 53.6M | 44.4M | 19.4M | 25.1M | 35.3M | |
Accumulated Other Comprehensive Income | (9.1M) | (11.3M) | (13.2M) | 9K | (4K) | 0.0 | |
Short Term Debt | 42.9M | 1.2M | 1.2M | 1.4M | 42.9M | 45.0M | |
Common Stock | 49K | 147K | 166K | 8K | 4K | 3.8K | |
Property Plant Equipment | 5.8M | 14.8M | 14.4M | 13.3M | 15.3M | 9.5M | |
Net Tangible Assets | (32.1M) | 8.7M | (12.9M) | (40.0M) | (36.0M) | (34.2M) | |
Current Deferred Revenue | 285K | 230K | 518K | 172K | 224K | 212.8K | |
Net Receivables | 2.8M | 5.1M | 5.1M | 2.2M | 1.4M | 2.2M | |
Retained Earnings Total Equity | (266.1M) | (317.2M) | (376.2M) | (423.0M) | (380.7M) | (399.7M) | |
Capital Surpluse | 267.4M | 328.5M | 342.1M | 431.5M | 496.3M | 308.8M | |
Inventory | 3.6M | 3.6M | 3.9M | 4.3M | 4.8M | 2.9M | |
Short Long Term Debt | 40.7M | 42.4M | 42.9M | 41.3M | 47.5M | 27.2M | |
Capital Lease Obligations | 3.9M | 10.5M | 9.4M | 9.6M | 8.2M | 6.1M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards T2 Biosystms in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, T2 Biosystms' short interest history, or implied volatility extrapolated from T2 Biosystms options trading.
Currently Active Assets on Macroaxis
When determining whether T2 Biosystms offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of T2 Biosystms' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of T2 Biosystms Stock. Outlined below are crucial reports that will aid in making a well-informed decision on T2 Biosystms Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for TTOO Stock analysis
When running T2 Biosystms' price analysis, check to measure T2 Biosystms' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy T2 Biosystms is operating at the current time. Most of T2 Biosystms' value examination focuses on studying past and present price action to predict the probability of T2 Biosystms' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move T2 Biosystms' price. Additionally, you may evaluate how the addition of T2 Biosystms to your portfolios can decrease your overall portfolio volatility.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is T2 Biosystms' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.19) | Revenue Per Share 2.756 | Quarterly Revenue Growth (0.69) | Return On Assets (0.85) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.